



## AUDITORS' REPORT

on

### Utilization of IPO Proceeds

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of Silva Pharmaceuticals Limited for the month ended 31 July 2020 as per required by Bangladesh Securities and Exchange and Commission (BSEC) under Section 2CC of the Securities and Exchange Ordinance 1969.

#### Management's Responsibility for the IPO proceeds Utilization

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 2, 3, 5 & 6 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated June 28, 2018 and other applicable laws and regulations.

#### Auditor's Responsibility

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 2, 3, 5 & 6 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated June 28, 2018 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Opinion

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 2, 3, 5 of PART- C of consent letter # BSEC/CI/IPO-269/2017/429, Dated June 28, 2018 and other applicable laws and regulations, gives a true and fair view of the statement for the month ended 31 July 2020.

#### We draw attention to the following matters:

During the verification, it was found that the revised IPO utilization plan which was approved by the shareholders was reported to the Bangladesh Securities and Exchange Commission (BSEC) and Chittagong Stock Exchange (CSE) vide later no. SPL/F&A/BSEC/2020/471, Dated March 03, 2020 and SILVAPHL/F&A/2020/473 dated March 05, 2020 respectively and we reported the necessary observation accordingly with the relevant monthly report.

The time frame for Utilization of IPO proceeds has been extended up to 09 October 2020 and approved by the shareholders on 18<sup>th</sup> AGM of the company held on 25 November 2019.



**As per TOR, we draw attention to the following matter:**

1. The Company has utilized accumulative amount of Tk. 60,532,650 up to 31 July 2020 which was 104.26% of the amount specified in the prospectus and thereafter revised utilization plan for the purpose of Civil Construction. As such, approval was a pre-requisite from the respected shareholders and concerned regulatory authority for the excess utilized amount of Tk. 2,474,124. During the month of July, 2020 no expenses has been incurred in respect of Civil Construction.
2. The Company has utilized accumulative amount of Tk. 24,999,020 which was 20.41% up to 31 July 2020 in respect of Purchase of Machinery and Equipment's. During the month of July, 2020 no expenses has been incurred in respect of Purchase new Machinery and Equipment's.
3. The Company has utilized Tk. 99,000,000 which was 100% of the budgeted amount up to 31 July 2020 for the purpose of loan repayment as specified in the prospectus.
4. The Company has utilized Tk. 20,441,474 which was 100% of the budgeted amount up to 31 July 2020 for the purpose of IPO expenses as specified in the prospectus and thereafter revised utilization plan.

**We also state that:**

- a) IPO proceeds have been utilized for the purposes as specified in the prospectus and thereafter revised utilization plan except the above said issues no.1 of the Company;
- b) IPO proceeds have been utilized in so far line with the conditions of the BSEC's consent letter for the IPO except the above said issues no. 1.
- c) Nothing has come to our attention except the COVID-19 situation that the Utilization of IPO proceeds will not be completed within the revised time frame as specified in the resolution of 18<sup>th</sup> AGM of the Company.
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the prospectus and 18<sup>th</sup> AGM of the Company.
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Date : 12 August 2020  
Dhaka.

**Pinaki & Company**  
Chartered Accountants





পিনাকী এণ্ড কোম্পানী  
Pinaki & Company

Chartered Accountants



Report on Utilization of IPO Proceeds  
For the Month of July 2020

Name of the Company: : Silva Pharmaceuticals Limited  
Amount (BDT) of capital raised through IPO: : BDT 300,000,000  
Date of Close of Subscription: : 05 August 2018  
Proceeds Receiving Date: : 10 October 2018  
Last Date of Full Utilization of IPO Fund as per Prospectus : As stated in time line columns

(Amount in BDT)

S.L	Purpose mentioned in the prospectus / 18th AGM	Time Line		Amount as per Prospectus	Amount as per 18th AGM	Status of Utilization						Remarks		
		As per Prospectus	As per 18th AGM			Opening	During the Month	Total Utilized Amount	Utilized %	Excess Utilized amount	Excess-utilized %		Total un utilized amount	Un -utilized %
1	Civil Construction	09.04.2020	09.10.2020	56,000,000	58,058,526	60,532,650	-	60,532,650	104.26	2,474,124	4.26	-	-	
2	Machinery and Equipment	09.04.2020	09.10.2020	122,500,000	122,500,000	24,999,020	-	24,999,020	20.41	-	-	97,500,980	79.59	
3	Repayment of Bank Borrowing at prospectus	09.01.2019	N/A	99,000,000	99,000,000	99,000,000	-	99,000,000	100.00	-	-	-	-	
4	IPO Expenses	N/A	N/A	22,500,000	20,441,474	20,441,474	-	20,441,474	100.00	-	-	-	-	
<b>Total</b>				<b>300,000,000</b>	<b>300,000,000</b>	<b>204,973,144</b>	<b>-</b>	<b>204,973,144</b>	<b>68.32</b>	<b>2,474,124</b>	<b>0.82</b>	<b>97,500,980</b>	<b>32.50</b>	

Notes:

- a) Actual application was received almost 25.76 Times.
- b) IPO proceeds have been utilized for the purposes/heads as specified in the prospectus and in line with the condition of the Commission's consent letter.
- c) Interest on IPO Proceeds in BDT (from FDR & SND) - 18,260,790
- d) Un-Utilized IPO Proceeds with interest income in BDT - 113,287,646

Silvana Mirza  
Chairman

Dr. Saira Khan  
Managing Director

Md. Abul Kasem  
Chief Financial Officer

Md. Al Hossain  
Company Secretary  
  
Pinaki & Company  
Chartered Accountants

12/08/2020

Registered Office : AHSANDELL, 2/A, Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000, Bangladesh  
Tel # 966-0944, 966-5095, 967-2726, Cell: 01317-201224, 01711-106302, E-mail : pinaki\_cc@yahoo.com website: www.pinaki.com.bd